ROLE OF RASAGALINE IN THE TREATMENT OF PARKINSON'S DISEASE


Дәйексөз келтіру

Толық мәтін

Аннотация

Parkinson's disease (PD) is the second most common neurodegenerative disease, which affects 1 to 2% of people over 60 years. Treatment of PD includes the symptomatic methods, and neuroprotective strategies remain elusive. Razagiline - a new, potent and irreversible monoamine oxidase type B inhibitor (MAO-B) which was approved for the treatment of PD. Razagiline more effective inhibits MAO-B as compared with selegiline, and the ability to use once a day is its advantage. Few large, randomized, placebo-controlled clinical trials have demonstrated the effectiveness of razagiline use as monotherapy at early stages of PD and as combination therapy for advanced stages of PD. The studies in vitro and in vivo have demonstrated the additional neuroprotective effects of rasagiline. Recently completed study ADAGIO with the inclusion of groups with delayed treatment (delayed disease progression against the background of use of razagiline once a day) have shown the potential of rasagaline for modification of clinical course dose 1 mg/day.

Әдебиет тізімі

  1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-35.
  2. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259-72.
  3. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
  4. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
  5. Olanow CW. Pathogenesis of cell death in Parkinson's disease. Mov Disord. 2007;22:S335-S342.
  6. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-622.
  7. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006;60:389-398.
  8. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol. 2007;20:453-464.
  9. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341-346.
  10. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354:424-425.
  11. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354:422-423.
  12. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord. 2002;8:297-309.
  13. Vogel WH, Orfei V, Century B. Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain. J Pharmacol Exp Ther. 1969;165:196-203.
  14. Tallman JF, Saavedra JM, Axelrod J. Biosynthesis and metabolism of endogenous tyramine and its normal presence in sympathetic nerves. J Pharmacol Exp Ther. 1976:199:216-221.
  15. Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain monoamine oxidase. Nature. 1970;225:817-20.
  16. Youdim MB, Collins GG, Sandler M, et al. Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature. 1972;236: 225-28.
  17. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991;30:666-72.
  18. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem. 1997;68:33-39.
  19. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm. 2003;110:509-15.
  20. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95-101.
  21. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci. 2005;1053:348-55.
  22. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-71.
  23. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-83.
  24. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology. 1992;42(4 Suppl 4):13-26.
  25. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 1984;303:359-64.
  26. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:228-34.
  27. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007;103:500-08.
  28. Finberg JP, Youdim MB. Modification of blood pressure and nictating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol. 1985;85:541-46.
  29. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-05.
  30. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-06.
  31. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-ldeprenyl and PET. J Nucl Med. 2005;46:1618-24.
  32. Thйbault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-05.
  33. Stern MB, Marek KL, Friedman J. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004;19:916-23.
  34. Azilect (rasagiline mesylate) [package inset]. Kansas City, MO: Teva Neuroscience; 2006.
  35. Hirsch EC, Hunot S, Faucheux B, et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord. 1999;14:383-85.
  36. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci. 1996;137:120-23.
  37. Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology. 2006;66:S69-S79.
  38. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996;47:S171-S183.
  39. Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J Neural Transm Suppl. 2007;(72):121-131.
  40. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport. 2000;11:3937-41.
  41. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SHSY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm. 2006;113:21-32.
  42. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187:455-59.
  43. Zhu W, Xie W, Pan T, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystininduced nigrostriatal dopaminergic degeneration. J Neurochem. 2008;105:1970-78.
  44. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotectiev in a transgenic model of multiple system atrophy. Exp Neurol. 2007;210:421-27.
  45. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidaze-B inhibitor, against closed head injury in the mouse. Eur J Pharmachol. 1999;366:127-35.
  46. Speiser Z, Mayk A, Litinetsky L, et al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J Neural Transm. 2007;114:595-05.
  47. Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004;251:1080-84.
  48. Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Ycells. J Neural Transm. 2002;109:467-81.
  49. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-43.
  50. Parkinson Study Group. A controlled, randomized delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-66.
  51. Parkinson Study Group. A randomized placebo-controlled trial with rasagiline in levodopa-treated patients with Parkinson Disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005;62:241-48.
  52. Rascol O, Brooks DJ, Melamed E, et al. Resagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Resagiline Given Once daily, study): a randomized, double blind, parallel-group trial. Lancet. 2005;365:947-54.
  53. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24:564-73.
  54. Suchowersky O, DeVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry. 1990;35:571-72.
  55. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48:1070-1076.
  56. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349-65.
  57. DeMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716-21.
  58. Goren T, Adar L, Sasson N. A clinical pharmacology study to determine the selective and non-selective doses of the monamine oxidase type B inhibitor, rasagiline. Neurology. 2009;72(Suppl 3):A320-A321.
  59. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004;291:358-64.
  60. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, doubleblind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23:2194-01.
  61. Olanow C, Rascol O, Hauser R; for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-78.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2010

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>